A second phase III study to evaluate gpASIT+ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

Trial Profile

A second phase III study to evaluate gpASIT+ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

Planning
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Grass pollen allergy immunotherapy-BioTech Tools (Primary)
  • Indications Allergic rhinoconjunctivitis
  • Focus Registrational; Therapeutic Use
  • Sponsors ASIT biotech
  • Most Recent Events

    • 19 Sep 2017 New trial record
    • 14 Sep 2017 According to an ASIT biotech media release, study is planned to start end of 2018 before the 2019 pollen season.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top